Stockscreener 앱 받기
2.27
6.97%
-0.17
전일 마감가:
$2.44
열려 있는:
$2.44
하루 거래량:
36,498
Relative Volume:
0.62
시가총액:
$7.10M
수익:
-
순이익/손실:
$-17.85M
주가수익비율:
-0.0612
EPS:
-37.0644
순현금흐름:
$-13.02M
1주 성능:
+7.08%
1개월 성능:
-13.03%
6개월 성능:
-78.23%
1년 성능:
-83.90%
1일 변동 폭
$2.24
$2.4892
1주일 범위
$1.93
$2.5699
52주 변동 폭
$1.6495
$51.75
Silexion Therapeutics Corp Stock (SLXN) Company Profile
명칭
Silexion Therapeutics Corp
전화
972-8-6286005
주소
12 ABBA HILLEL ROAD, RAMAT GAN
SLXN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
2.27 | 7.63M | 0 | -17.85M | -13.02M | -37.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스
Silexion reports breakthrough in KRAS cancer therapy - MSN
Signal Recap: What is the PEG ratio of Silexion Therapeutics Corp Equity Warrant2025 Key Lessons & Detailed Earnings Play Strategies - baoquankhu1.vn
Is Silexion Therapeutics Corp a defensive stockAnalyst Upgrade & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Opening Moves & Fast Gain Swing Alerts - Улправда
Why Silexion Therapeutics Corp Equity Warrant stock attracts high net worth investorsFit and Size Notes & quick comparison of popular models - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock beat market expectations this quarterRecession Risk & Fast Exit Strategy with Risk Control - Улправда
Dividend Watch: Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - Улправда
Is Silexion Therapeutics Corp stock a buy for dividend growthJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - ulpravda.ru
Why retail investors favor Silexion Therapeutics Corp stockQuarterly Market Review & Free High Accuracy Swing Entry Alerts - ulpravda.ru
How strong is Silexion Therapeutics Corp stock revenue growthProduct Launch & Entry Point Confirmation Signals - Улправда
Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - Улправда
What momentum indicators show for Silexion Therapeutics Corp Equity Warrant stockMarket Performance Recap & Free Long-Term Investment Growth Plans - ulpravda.ru
Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Spike Watch & Daily Entry Point Trade Alerts - Улправда
Can Silexion Therapeutics Corp stock weather global recession2025 Price Action Summary & Short-Term High Return Strategies - Улправда
Signal Recap: What technical signals suggest for Silexion Therapeutics Corp stockWeekly Market Report & Consistent Growth Equity Picks - ulpravda.ru
Will Silexion Therapeutics Corp stock outperform Dow Jones indexTrade Entry Summary & Community Driven Trade Alerts - ulpravda.ru
Silexion Therapeutics CorpOrdinary Shares (NQ: SLXN - FinancialContent
Silexion outlines 2026 plans after transformational 2025 progress - TipRanks
Silexion Therapeutics Corp Highlights 2025 Achievements and 2026 Milestones - TradingView — Track All Markets
Silexion Therapeutics' Cancer Drug to Enter Human Trials in Early 2026 - marketscreener.com
Silexion Therapeutics Reports Promising Preclinical Results for SIL204 in KRAS-Driven Cancers and Plans Phase 2/3 Trial Initiation for 2026 - Quiver Quantitative
Silexion Therapeutics Releases CEO Letter to Shareholders - GlobeNewswire
Cash per share of Silexion Therapeutics Corp Warrant – NASDAQ:SLXNW - TradingView — Track All Markets
Merger Talk: Is Silexion Therapeutics Corp Equity Warrant stock trading at a premium valuation2025 Top Decliners & Daily Volume Surge Signals - Bộ Nội Vụ
Risk Hedge: Will Silexion Therapeutics Corp stock deliver strong dividend growth2025 Market Overview & Safe Capital Growth Stock Tips - Bộ Nội Vụ
Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsJuly 2025 Retail & Free Technical Pattern Based Buy Signals - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock hit record highs againJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - Улправда
Will Silexion Therapeutics Corp Equity Warrant stock pay special dividendsTrade Exit Report & Weekly Top Performers Watchlists - DonanımHaber
How Silexion Therapeutics Corp stock compares to growth peersQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber
Risk Analysis: Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsPortfolio Risk Report & High Conviction Trade Alerts - Улправда
Treasury Yields: How strong is Silexion Therapeutics Corp stock revenue growthWeekly Trade Report & AI Based Buy and Sell Signals - DonanımHaber
Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Zacks Research - Defense World
Can Silexion Therapeutics Corp stock sustain free cash flow growth2025 Year in Review & Fast Exit/Entry Strategy Plans - Улправда
Gains Report: Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Recap & AI Driven Stock Price Forecasts - Улправда
Stop Loss: Can Silexion Therapeutics Corp Equity Warrant stock hit record highs again - Улправда
Silexion Therapeutics submits Phase 2/3 trial application - MSN
Silexion Therapeutics Submits Phase 2/3 Trial Application - TipRanks
Silexion submits Phase 2/3 trial application to Israel for SIL204 - TipRanks
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 - TradingView — Track All Markets
Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer - Quiver Quantitative
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for Sil204 in Locally Advanced Pancreatic Cancer - marketscreener.com
Silexion Therapeutics (NASDAQ:SLXN) Now Covered by Litchfield Hills Research - Defense World
Silexion Therapeutics initiated with a buy at Litchfield Hills - MSN
Silexion Therapeutics initiated with a Buy at Litchfield Hills - TipRanks
Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga
How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks
Silexion Therapeutics drops 18%, prices $5M share offering - MSN
Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks
Silexion Therapeutics Corp (SLXN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):